Clinical Trial Results:
A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) with a Lead-in, Open-Label, Single-Dose Relative Bioavailability Study of LX6171 Oral Suspension in Healthy Elderly Subjects
Summary
|
|
EudraCT number |
2007-005241-38 |
Trial protocol |
NL |
Global completion date |
23 Oct 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Nov 2021
|
First version publication date |
25 Nov 2021
|
Other versions |
|
Summary report(s) |
CSR Synopsis-LX6171.201-AAMI |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.